Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease
Abstract. Alzheimer's disease (AD) is a neurodegenerative disease that gradually impairs cognitive functions. Recently, there has been a conceptual shift toward AD to view the disease as a continuum. Since AD is currently incurable, effective intervention to delay or prevent pathological cognit...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2023-03-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002566 |
| _version_ | 1797840192523993088 |
|---|---|
| author | Xianfeng Yu Kai Shao Ke Wan Taoran Li Yuxia Li Xiaoqun Zhu Ying Han Yuanyuan Ji |
| author_facet | Xianfeng Yu Kai Shao Ke Wan Taoran Li Yuxia Li Xiaoqun Zhu Ying Han Yuanyuan Ji |
| author_sort | Xianfeng Yu |
| collection | DOAJ |
| description | Abstract. Alzheimer's disease (AD) is a neurodegenerative disease that gradually impairs cognitive functions. Recently, there has been a conceptual shift toward AD to view the disease as a continuum. Since AD is currently incurable, effective intervention to delay or prevent pathological cognitive decline may best target the early stages of symptomatic disease, such as subjective cognitive decline (SCD), in which cognitive function remains relatively intact. Diagnostic methods for identifying AD, such as cerebrospinal fluid biomarkers and positron emission tomography, are invasive and expensive. Therefore, it is imperative to develop blood biomarkers that are sensitive, less invasive, easier to access, and more cost effective for AD diagnosis. This review aimed to summarize the current data on whether individuals with SCD differ reliably and effectively in subjective and objective performances compared to cognitively normal elderly individuals, and to find one or more convenient and accessible blood biomarkers so that researchers can identify SCD patients with preclinical AD in the population as soon as possible. Owing to the heterogeneity and complicated pathogenesis of AD, it is difficult to make reliable diagnoses using only a single blood marker. This review provides an overview of the progress achieved to date with the use of SCD blood biomarkers in patients with preclinical AD, highlighting the key areas of application and current challenges. |
| first_indexed | 2024-04-09T16:10:50Z |
| format | Article |
| id | doaj.art-25f2ab900f774fb387f491c3802a31cc |
| institution | Directory Open Access Journal |
| issn | 0366-6999 2542-5641 |
| language | English |
| last_indexed | 2024-04-09T16:10:50Z |
| publishDate | 2023-03-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj.art-25f2ab900f774fb387f491c3802a31cc2023-04-24T10:07:12ZengWolters KluwerChinese Medical Journal0366-69992542-56412023-03-01136550552110.1097/CM9.0000000000002566202303050-00001Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's diseaseXianfeng YuKai ShaoKe WanTaoran LiYuxia LiXiaoqun ZhuYing HanYuanyuan JiAbstract. Alzheimer's disease (AD) is a neurodegenerative disease that gradually impairs cognitive functions. Recently, there has been a conceptual shift toward AD to view the disease as a continuum. Since AD is currently incurable, effective intervention to delay or prevent pathological cognitive decline may best target the early stages of symptomatic disease, such as subjective cognitive decline (SCD), in which cognitive function remains relatively intact. Diagnostic methods for identifying AD, such as cerebrospinal fluid biomarkers and positron emission tomography, are invasive and expensive. Therefore, it is imperative to develop blood biomarkers that are sensitive, less invasive, easier to access, and more cost effective for AD diagnosis. This review aimed to summarize the current data on whether individuals with SCD differ reliably and effectively in subjective and objective performances compared to cognitively normal elderly individuals, and to find one or more convenient and accessible blood biomarkers so that researchers can identify SCD patients with preclinical AD in the population as soon as possible. Owing to the heterogeneity and complicated pathogenesis of AD, it is difficult to make reliable diagnoses using only a single blood marker. This review provides an overview of the progress achieved to date with the use of SCD blood biomarkers in patients with preclinical AD, highlighting the key areas of application and current challenges.http://journals.lww.com/10.1097/CM9.0000000000002566 |
| spellingShingle | Xianfeng Yu Kai Shao Ke Wan Taoran Li Yuxia Li Xiaoqun Zhu Ying Han Yuanyuan Ji Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease Chinese Medical Journal |
| title | Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease |
| title_full | Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease |
| title_fullStr | Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease |
| title_full_unstemmed | Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease |
| title_short | Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease |
| title_sort | progress in blood biomarkers of subjective cognitive decline in preclinical alzheimer s disease |
| url | http://journals.lww.com/10.1097/CM9.0000000000002566 |
| work_keys_str_mv | AT xianfengyu progressinbloodbiomarkersofsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT kaishao progressinbloodbiomarkersofsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT kewan progressinbloodbiomarkersofsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT taoranli progressinbloodbiomarkersofsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT yuxiali progressinbloodbiomarkersofsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT xiaoqunzhu progressinbloodbiomarkersofsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT yinghan progressinbloodbiomarkersofsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT yuanyuanji progressinbloodbiomarkersofsubjectivecognitivedeclineinpreclinicalalzheimersdisease |